Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma
Authors:
- Laura FeeneyLFLaura Feeney
- Yatin JainYJYatin Jain
- Matthew BeasleyMBMatthew Beasley
- Oliver DonnellyODOliver Donnelly
- Anthony KongAnthony Kong
- Rafael MoleronRMRafael Moleron
- Chandran NallathambiCNChandran Nallathambi
- Martin RollesMRMartin Rolles
- Paul SangheraPSPaul Sanghera
- Aung TinATAung Tin
- Danny UlahannanDUDanny Ulahannan
- Harriet S. WalterHWHarriet S. Walter
Open Access
Abstract
Adenoid cystic carcinoma (ACC) is a rare cancer of secretory glands. Recurrent or metastatic (R/M) ACC is generally considered resistant to cytotoxic chemotherapy. Recent phase II studies have reported improved objective response rates (ORR) with the use of the multi-kinase inhibitor lenvatinib. We sought to evaluate real-world experience of R/M ACC patients treated with lenvatinib monotherapy within the UK National Health Service (NHS) to determine the response rates by Response Evaluation Criteria of Solid Tumour (RECIST) and clinical outcomes. Twenty-three R/M ACC patients from eleven cancer centres were included. All treatment assessments for clinical decision making related to drug therapy were undertaken at the local oncology centre. Central radiology review was performed by an independent clinical trial radiologist and blinded to the clinical decision making. In contrast to previously reported ORR of 12–15%, complete or partial response was not observed in any patients. Eleven patients (52.4%) had stable disease and 5 patients (23.8%) had progression of disease as the best overall response. The median time on treatment was 4 months and the median survival from discontinuation was 1 month. The median PFS and OS from treatment initiation were 4.5 months and 12 months respectively. Multicentre collaborative studies such as this are required to evaluate rare cancers with no recommended standard of care therapy and variable disease courses.Keywords
This publication has 33 references indexed in Scilit:
- Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic RamificationsClinical Cancer Research, 2014
- Phase II study of gefitinib in patients with advanced salivary gland cancersHead & Neck, 2014
- Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neckHead & Neck, 2013
- Adenoid cystic carcinoma of the head and neckCancer, 2012
- A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACCAnnals of Oncology, 2011
- Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literatureJournal of Medical Case Reports, 2011
- Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic reviewThe Lancet Oncology, 2011
- Transrectal drainage of a diverticular abscess using a pigtail catheter without radiological guidance: a case reportJournal of Medical Case Reports, 2011
- Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neckProceedings of the National Academy of Sciences, 2009
- A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glandsOral Oncology, 2007